pipette
ENEnglish

Medication history, not clinical profiles, predicts antihypertensive treatment persistence across health systems

S. Wang, D. Lu, T. Tao

PreprintUso en el mundo real

En palabras de los autores

Background. Hypertension control remains poor worldwide, in large part because patients discontinue antihypertensive treatment. Machine-learning (ML) prediction models for medication persistence are typically single-country and cross-sectional, rarely compared with simple clinical information, and lack external validation across health systems. Methods. We harmonized three prospective aging cohorts -- the China Health and Retirement Longitudinal Study (CHARLS), the Survey of Health, Ageing and Retirement in Europe (SHARE), and the US Health and Retirement Study (HRS) -- including adults aged >=50 years with doctor-diagnosed hypertension at baseline and known medication status at follow-up. We used baseline plus two prior waves to predict non-use of any antihypertensive medication at the next wave (treatment non-persistence), with 21 harmonized cross-sectional features, 11 longitudinal history features (including the prior non-use ratio), and a 3-feature parsimonious medication-history score (baseline non-use, prior non-use ratio, prior discontinuation). Models were L2-regularized logistic regression and random forest, evaluated by 5-fold x 5-repeat nested cross-validation and by direct transport of a CHARLS-trained model to SHARE and HRS without retraining. Three simple rule-based comparators were prespecified: baseline carry-forward (T0), prior non-use count (T1), and the 3-feature score (T2). Non-inferiority of T2 versus the full 32-feature logistic model was tested at delta=0.03 AUC. Country-level external validation across 18 SHARE countries used random-effects meta-analysis and inverse-variance meta-regression on World Bank indicators. Results. The analytic samples comprised 4,532 (CHARLS), 26,128 (SHARE) and 9,495 (HRS) participants, with non-persistence of 22.8%, 19.1% and 12.6%. Within each cohort, adding medication history raised AUC from 0.59-0.67 to 0.78-0.85 (Delta AUC 0.17-0.20; all 95% CIs >0). On direct transport, history models retained AUC 0.73-0.76 in SHARE and 0.83-0.85 in HRS, whereas cross-sectional models collapsed to near chance in SHARE (AUC 0.55-0.57). The baseline carry-forward rule alone achieved AUC 0.70-0.80; the 3-feature score achieved 0.75-0.83 and was non-inferior to the full logistic model (Delta AUC <=0.027; upper CI bounds <0.03) in all three within-cohort comparisons and both transport targets. Across 18 European countries, cross-sectional models pooled at 0.55 (I^2=30%) while history models pooled at 0.74-0.76 (I^2=82-88%); transported AUC increased with national wealth (r=0.58, P=0.011), and calibration slope declined with non-persistence burden (r=-0.69, P=0.002) and out-of-pocket expenditure share (r=-0.51, P=0.032). Conclusions. A parsimonious medication-history core transfers across health systems, whereas cross-sectional clinical profiles do not. Complex ML adds little beyond a one-question or three-variable medication-history rule. Discrimination is strongest in high-resource, low-burden systems, but probability calibration degrades where non-persistence is common, requiring local recalibration before individual-level use.

Resultado principalLimitación que admiten los autores

Apareció: jueves, 5 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.02.26367145